Serum CRP Levels In Patients Research Articles

Evaluation of serum CRP levels in patients with sepsis at intensive care unit

Amaç: Sepsiste meydana gelen inflamatuar yanıt, prognoz göstergesi olabilen biyobelirteçlerin salınımına neden olmaktadır. Çalışmamızda yoğun bakım kliniğinde 30 gün ve daha az süre yatan hastalarda CRP, PCT, Laktat düzeyleri ve SOFA Skoru değişimleri ile bunların prognoz tahminindeki yerinin değerlendirilmesi amaçlandı. Gereç ve Yöntem: Anesteziyoloji ve Reanimasyon Anabilim Dalı Yoğun Bakım Kliniğinde yatarak tedavi gören 485 hasta randomize olarak çalışmaya dahil edildi ve dosya bilgileri retrospektif olarak incelendi. Hastaların yaş, cinsiyet, yoğun bakımda yatış süreleri, yoğun bakıma yatışta ve yoğun bakımda izlendikleri günlerdeki sepsis tanı kriterleri, serum CRP, PCT, laktat düzeyleri, SOFA ve APACHE II skorları kaydedildi. Hastaların yoğun bakımda yattıkları tüm günler için sepsis tanıları (sepsisin olmadığı dönem / sepsis / ağır sepsis / septik şok) 2001 konsensus ve 2008 Surviving Sepsis Campaign rehberine göre kondu. Bulgular: Ortalama yaş 51,1 ± 20,6, ortalama APACHE II skoru ise 23,2 ± 8,9 olarak belirlendi. Hastaların 35’i yoğun bakımdan taburcu (%7,21), 164’ü hastane içi diğer kliniğe sevk edilirken (%33,82) 286 hastada (%58,97) eksitus gerçekleştiği görüldü. Hastaların 178’i yoğun bakım yatış süresince sepsis tanısı almadı. Hastaların 307’sinin ise sepsis, ağır sepsis ya da septik şok tanılarından biri ya da fazlasını aldığı saptandı. Sepsis, ağır sepsis ve septik şok tanısı alan hastaların ortalama CRP değerleri sırasıyla 9,33, 13,76 ve 16,77 mg/dl olarak; PCT ortalama değerleri ise 1,66, 5,23 ve 12,42 ng/ml olarak bulundu. Hastaların 35’i yoğun bakımdan taburcu (%7,21), 164’ü diğer kliniğe sevk edilirken (%33,82), 286 hastada (%58,97) eksitus gerçekleştiği görüldü. Eksitus olan grupta son CRP değerinin ilk ölçülen CRP değerine oranı; taburcu ve diğer kliniklere nakil olan gruba göre istatistiksel olarak yüksek bulundu. Sonuç: Serum CRP düzeyinin sepsisin ciddiyetine paralel olarak arttığı ve sepsiste güvenilir bir prognostik faktör olduğu kanısına varıldı.

Su1654 – The Prevalence of Hla-Dq Genes, Celiac Serologies, Iga Levels, and Serum Crp Levels in Patients with Microscopic Colitis

Su1654 – The Prevalence of Hla-Dq Genes, Celiac Serologies, Iga Levels, and Serum Crp Levels in Patients with Microscopic Colitis

Clinical efficacy and effects on CRP levels of ambroxol in treatment of pulmonary infections

Objective To study the clinical efficacy and effects on CRP levels of ambroxol in treatment of pulmonary infections. Methods 68 patients with pulmonary infection were selected and divided into the observation group(n=34) and control group by using the random number table method(n=34). The observation group was treated with ammonia bromine atomization inhalation treatment, while the control group was treated with alpha chymotrypsin atomization inhalation therapy.The clinical effect and duration of symptoms and signs disappeared of the two groups were compared, and serum CRP level changes in the two groups before and after treatment were also compared. Results After treatment, the clinical total effective rate was 91.2% of the observation group.And the total effective rate was 70.6% in control group, the comparison between the two groups had statistically significant difference (χ2=4.316, P<0.05). Compared with the control group, the observation group patients symptoms disappear time(3.1±0.5)d, pulmonary symptoms disappear time(4.1±1.7)d, body temperature returned to normal time(4.1±1.6)d and hospital stay(8.4±2.8)d were significantly shortened, the differences were statistically significant (t=2.879, 2.918, 3.025, 3.972, all P<0.05). The serum CRP levels in patients of the observation group was (22.45±9.27)mg/L, which of the control group was (33.45±14.67)mg/L, both were significantly lower than before treatment, the difference was statistically significant (t=6.314, 5.126, all P<0.05). The lower degree of serum CRP level in the observation group was obviously better than tha in the control group, the difference was statistically significant (t=6.263, P<0.05). Conclusion The ambroxol can achieve significant clinical effect on treatment of pulmonary infections, which can significantly shorten the patient's symptoms and lung signs disappear time and length of hospital stay, etc.It can reduce the serum CRP level, and is worth popularization and application in clinic. Key words: Respiratory tract infections; C-reactive protein; Ambroxol

Effect of edaravone on serum CRP in patients with cerebral infarction after thrombolytic therapy

Objective To investigate the therapeutic effect and the level of C-reactive protein of Edaravone on acute cerebral infarction after thrombolytic therapy in urokinase,and to discuss edaravone on brain tissue protective effect of thrombolytic. Methods 41 patients with cerebral infarction were,divided into 2 groups randomly:treatment group(19cases) and control group(22 cases). Control group received thrombolytic therapy,and treatment group was treated with Edaravone at a dose of 30mg,twice a day,for 14 days. Clinical outcomes and neurological deficit score were evaluated before and after treatment. At the same time, serum CRP levels in patients were determend by immune turbidimetry. Results The treatment group whose neurological deficit score better than the control group ( P ＜ 0.05),the total effective rate was significantly higher( P ＜ 0.01 ) ,compared with the control group, the treatment group CRP levels were significantly lower ( P ＜ 0. 05 ). ConclusionEdaravone on acute cerebral infarction in patients after thrombolysis can significantly improve the clinical efficacy, reduce serum CRP levels, recovery and prognosis of cerebral infarction is important, Edaravone can significantly improve neurological function in patients with acute cerebral infarction,protects against cerebral ischemia after thrombolysis in metabolic poisons further damage. Key words: Acute cerebral infarction; Urokinase; C-reactive protein; Edaravone

C-reactive protein level is decreased in patients with Alzheimer's disease and related to cognitive function and survival time

Background Previous studies have observed decreased serum CRP levels in patients with established Alzheimer's disease (AD) compared to controls or other diagnostic groups of elderly patients with mental illness. Methods We have investigated the relation between CRP level and the severity of AD as assessed by cognitive function, brain imaging and survival time. Results Patients with AD showed overall lower CRP levels than other patients with mental illness, but elevated CRP levels in these patients were associated with lower cognitive function and shorter survival time. Conclusion The reason for an overall low CRP level is not obvious. Elevated CRP level in patients with AD suggests the presence of inflammatory activity in this subgroup of patients that may benefit from anti-inflammatory administration.

C‐reactive protein polymorphism and Crohn's disease: authors' reply

Sir, Thank you for commenting on our study published in AP&T (1). However, we disagree on the comments made by Szalai and Alarcón (2): We never stated that the +1059G/C CRP polymorphism is associated with Crohn's disease (CD). Instead, we pointed out in this article: ‘Our results demonstrate that the CRP +1059G/C polymorphism is not over-represented in CD patients compared with the normal population…’ (see page 1111 of Ref. 1). In particular, none of the P-values comparing the genotypes in patients with CD with healthy controls demonstrated significance in our analysis (Table 3). Therefore, our conclusion was not – as claimed by Szalai and Alarcón – that this polymorphism is associated with CD, but that this polymorphism is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with CD. This conclusion was not solely based on 5 CC homozygous patients but on all carriers of C alleles, which form the combined group of CC homozygous (n = 5) and GC heterozygous carriers (n = 17), compared with all wild-type carriers (n = 219). All P-values given in Table 3 are >0.05 (and not <0.05 as assumed by Szalai and Alarcón) and therefore not significant, which is consistent with the result of the chi-squared test as performed by Szalai and Alarcón.2 Given our P-values in Table 2 and our explanations in the figure legend and the corresponding text in the Results and Discussion sections, it should have become clear that the conclusions drawn were not based on only five homozygous patients with the CC genotype but rather on the combined group of GC (n = 17) and CC genotypes (n = 5). Performing the analysis with the combined L1 phenotype (ileal involvement) and L3 phenotype (ileocolonic involvement), as suggested by Szalai and Alarcón, the prevalences were as follows: 58.4% among GG wild-type carriers (128/219), 88.2% among GC heterozygotes (15/17), and 80% among CC homozygotes (4/5). Analysing the resulting 3-by-2 Table (three genotypes vs. ileal involvement yes/no), as suggested by Szalai and Alarcón, yields a P-value below α = 0.05, namely P = 0.029 (Fisher's exact test). Given that GG wild-type patients are by far the largest genotype group (90.9%) of all patients analysed, it is not unexpected that they also are the largest patient group with ileal involvement, as they are in all other phenotype categories: L1 (72.7%), L2 (97.9%), L3 (89.6%), L4 (95.7%). Nonetheless, GG wild-type patients are relatively underrepresented in the L1 group (ileal involvement only). In view of the exploratory, i.e. rather hypothesis-generating than confirmatory, character of our analyses, we agree with Szalai and Alarcón that large studies are necessary to confirm our results. This point was discussed in great detail in the Discussion section of our article (for details see page 1112/1113 of ref. 1), which also included a power calculation. Depending on the prevalence of the CC genotype in different populations, between 1042 and 25000 patients would be necessary to demonstrate with 80% power an association of CC homozygosity with CD, which clearly can only be achieved in a large multicentre study, but also demonstrates that this polymorphism is not a major contributor to overall disease susceptibility for CD.